Catalyst Biosciences Inc
CBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$531.9M
Close$
$19.84
38.6% upside
Current Fair Value
38.6% upsideUndervalued by 38.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $531.90 Million |
|---|---|
| Enterprise Value | $364.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-14.78 |
| Beta | 1.26 |
| Outstanding Shares | 30,532,234 |
Return
| Return on Equity | -76.25% |
|---|---|
| Return on Assets | -68.11% |
| Return on Invested Capital | -106.85% |
Valuation & Multiples
| P/E Ratio | -1.89 |
|---|---|
| PEG | 1.89 |
| Price to Sales | -14.32 |
| Price to Book Ratio | 2.86 |
| Enterprise Value to Revenue | -12.36 |
| Enterprise Value to EBIT | -2.08 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.74
Average shareholder expectationRevenue Estimate
$357,143
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.67
Average shareholder expectationRevenue Estimate
$357,143
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 95.52%▲ 12.90% |
|---|---|
| Total Invested | $524.96M▲ 13.81% |
| Investors Holding | 82▲ 22.00% |
ESG Score
No data
About Catalyst Biosciences Inc
CEO: Nassim Usman